ResearcherSemmelweis UniversityActive in the last 2 years

József Tı́már

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9183-0859; OpenAlex author ID A5067140213. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 2

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 3

Antimetastatic effects of MRTX1133 KRAS G12D specific inhibitor in a liver metastatic model of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-025-34204-y ↗
Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer. Last author DOI 10.3389/pore.2024.1611948 ↗
[Molecular classification of pancreatic cancer]. Co-author PMID 34614040 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Krisztina Andrea Szigeti · 2 shared papers, 2024–2026 · strength 0.54
- Paper Antimetastatic effects of MRTX1133 KRAS G12D specific inhibitor in a liver metastatic model of pancreatic ductal adenoc… DOI 10.1038/s41598-025-34204-y ↗
- Paper Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreati… DOI 10.3389/pore.2024.1611948 ↗
Eszter Molnár · 1 shared paper, 2024 · strength 0.21
- Paper Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreati… DOI 10.3389/pore.2024.1611948 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.